Effect of vildagliptin in treatment of experimentally induced {u2013}ulcerative colitis in rats / Marina Ramsis Fouad Youssef ; Supervised Hala Ahmed Fahmy Zaki , Ayman Elsayed Mohamed Elsahar , Rania Mohamed Kamel Hassan Mohamed Salama

By:

Marina Ramsis Fouad Youssef

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Marina Ramsis Fouad Youssef , 2021Description: 136 P. : charts , facsimiles ; 25cmOther title:

دراسة تأثير ال{u٠٦ء٤}لداجلبتن فى نموذج تجريبى لالتهاب القولون التقرحى فى الجرذان [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology Summary: Ulcerative colitis (UC) is a chronic bowel disease depicted by the involvement of pro-inflammatory cytokines.The release of these cytokines is regulated by phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/nuclear factor-kappa B (NFmB) and cAMP response element-binding protein (CREB) signaling pathways as well as over expression of microRNA 146a (miR-146a) and long non-coding RNA interferon gamma antisense 1 (lncRNA IFNG-AS1). Vildagliptin (Vilda), a dipeptidyl peptidase IV (DPP-IV) inhibitor, has an anti-inflammatory, antioxidant and anti-apoptotic effects which were established in various models. However, its possible protective effect in UC has not been clarified. Hence, the current study aimed to explore the possible prophylactic effect of different doses of Vilda against acetic acid (AA)-induced UC in rats. Forty-eight adult male Wistar rats were divided into six groups: control, Vilda (10 mg/kg/day; p.o.), AA, AA+Vilda (5 mg/kg/day; p.o.), AA+Vilda (10 mg/kg/day; p.o.) and AA+sulfasalazine (Sulfa) (100 mg/kg/day; p.o.).Low- and high-dose Vilda showed a significant improvement in the disease activity index (DAI) and macroscopic assessment markers. Vilda has markedly modulated the expression of lncRNA IFNG-AS1 and miR-146a, as well as PI3K/Akt/NFmB, CREB and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathways, which was reflected in alleviated oxidative stress, inflammation and apoptosis. Such outcomes were more prominent with the high-dose Vilda against low-dose Vilda and Sulfa. Moreover, the histological examination showed almost intact histological features in Vilda-treated groups when compared to AA group. In conclusion, Vilda can be regarded as a new promising therapeutic alternative against UC with higher benefit shown with high-dose Vilda

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Date due	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.08.09.M.Sc.2021.Ma.E (Browse shelf(Opens below))		Not for loan		01010110084004000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.08.09.M.Sc.2021.Ma.E (Browse shelf(Opens below))	84004.CD	Not for loan		01020110084004000

Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology

Ulcerative colitis (UC) is a chronic bowel disease depicted by the involvement of pro-inflammatory cytokines.The release of these cytokines is regulated by phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/nuclear factor-kappa B (NFmB) and cAMP response element-binding protein (CREB) signaling pathways as well as over expression of microRNA 146a (miR-146a) and long non-coding RNA interferon gamma antisense 1 (lncRNA IFNG-AS1). Vildagliptin (Vilda), a dipeptidyl peptidase IV (DPP-IV) inhibitor, has an anti-inflammatory, antioxidant and anti-apoptotic effects which were established in various models. However, its possible protective effect in UC has not been clarified. Hence, the current study aimed to explore the possible prophylactic effect of different doses of Vilda against acetic acid (AA)-induced UC in rats. Forty-eight adult male Wistar rats were divided into six groups: control, Vilda (10 mg/kg/day; p.o.), AA, AA+Vilda (5 mg/kg/day; p.o.), AA+Vilda (10 mg/kg/day; p.o.) and AA+sulfasalazine (Sulfa) (100 mg/kg/day; p.o.).Low- and high-dose Vilda showed a significant improvement in the disease activity index (DAI) and macroscopic assessment markers. Vilda has markedly modulated the expression of lncRNA IFNG-AS1 and miR-146a, as well as PI3K/Akt/NFmB, CREB and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathways, which was reflected in alleviated oxidative stress, inflammation and apoptosis. Such outcomes were more prominent with the high-dose Vilda against low-dose Vilda and Sulfa. Moreover, the histological examination showed almost intact histological features in Vilda-treated groups when compared to AA group. In conclusion, Vilda can be regarded as a new promising therapeutic alternative against UC with higher benefit shown with high-dose Vilda

Issued also as CD

There are no comments on this title.

to post a comment.